Treatments
927 articles
CAR T Cell Trial Targets Mesothelin
In an immunotherapy clinical trial, Dr. Mark O’Hara is using CAR T cells to attack mesothelin-expressing tumor cells in pancreatic cancer.
Representing Genetic and Clinical Diversity in Pancreatic Cancer
Dr. Kentaro Sudo explores the possible causes for different responses to drugs among ethnic groups, pointing to the need for clinical diversity in trials.
Two Enzymes May Predict Pancreatic Cancer Severity and Development
Dr. Alexandra Newton and her lab have found that the relationship between two enzymes common to cancer may play a role in pancreatic cancer prognosis.
A New Immunotherapy Combination for Metastatic Pancreatic Cancer
Researchers are looking at a combination of two types of monoclonal antibodies to treat advanced pancreatic cancer.
Testing a Thyroid Cancer Drug to Treat Advanced Pancreatic Neuroendocrine Tumors
Researchers are testing a thyroid drug to see if it is effective against pancreatic neuroendocrine tumors, among other cancers.
A Vaccine To Boost Immune Response to Pancreatic Cancer
Researchers are testing whether a vaccine can heighten the body’s immune response to pancreatic cancer after surgical removal of the tumor.
Drug Combination to Combat Pancreatic and other Gastrointestinal Cancers
Researchers are testing a drug combination of TAS-102, an approved drug for colorectal cancer, and nanoliposomal irinotecan, on gastrointestinal cancers.
Adding A Noninvasive Surgical Technique to Standard Treatment for Locally Advanced Pancreatic Cancer
A clinical trial compares standard treatment plus irreversible electroporation to standard treatment alone for locally advanced pancreatic cancer.
Radiation and Chemotherapy to Make Pancreatic Cancer Surgically Removable
Can a combination of radiation and chemotherapy make pancreatic tumors that are borderline removeable better candidates for surgery? A clinical trial looks at this question.
Trying a New Type of Treatment to Stop Advanced Pancreatic Cancer
Researchers test the chemotherapy combination of AM0010 and FOLFOX as a second-line therapy for people with metastatic pancreatic cancer.
A Novel Combination to Slow Pancreas Tumors that Cannot Be Surgically Removed
Can a combination of standard drugs, a PARP inhibitor, and intensity modulated radiation therapy to slow pancreatic tumor growth?